When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps.

Well, I've got one that's already started -- and is likely to continue along the path to biotech stardom. Right now, this particular player has fallen out of favor. But there's reason to believe this company will become a biotech giant by 2030.

I'm talking about (NASDAQ: MRNA). And its successes won't necessarily be tied uniquely to its blockbuster coronavirus vaccine. Let's find out how Moderna may become one of the industry's leading players.

Continue reading

Source Fool.com